Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients with Carcinoid Syndrome (CS): Results From the SymNET Study

Philippe Ruszniewski1; Martyn E. Caplin2; Juan W. Valle3; Catherine Lombard-Bohas4; Graeme Poston5; Petros Perros6; Luboš Holubec7; Gianfranco Delle Fave8; Denis Smith9; Patricia Niccoli10; Pascal Maisonneuve11; Edda Gomez-Panzani12

1Beaujon Hospital, F-92118 Clichy, France
2Royal Free Hospital, London NW3 2QG, UK
3Christie NHS Foundation Trust, Manchester M20 4BX, UK
4Edouard-Herriot Hospital, 69003 Lyon, France
5University Hospital Aintree, Liverpool L9 7AL, UK
6Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK
7Teaching Hospital Plzen, 301 00 Plzen–Bory, Czech Republic
8Ospedale Sant’ Andrea, 00189 Rome, Italy
9Saint André Hospital, 33000 Bordeaux, France
10CHU Timone, 13005 Marseille, France
11Ipsen, 92100 Boulogne-Billancourt, France
12Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ 07920, USA

Background: CS associated with NETs can have a negative impact on patients’ QoL. Here, QoL data are evaluated from the SymNET study.

Methods: The SymNET study was a large observational trial involving patients with a NET and a history of CS-related diarrhea (NCT01234168). Patients had been treated with LAN for >3 months. Patient-reported outcomes were assessed at a routine clinic visit. The primary endpoint was patient satisfaction with diarrhea control (PSD). Symptoms were evaluated using medical records. QoL was assessed using the EORTC QLQ-C30 and QLQ-GI.NET21 questionnaires, which assess functional dimensions (QLQ-C30; higher scores = better QoL) and symptoms (QLQ-C30 and QLQ-GI.NET21; lower scores = better QoL). Overall QoL was evaluated according to satisfaction with CS symptom control.

Results: Among 273 patients enrolled, 76% [95% CI: 70, 81] were ‘completely’ or ‘rather’ satisfied with diarrhea control. There was a clinically significant reduction in stool number and statistically significant improvements in urgency, leakage, and associated pain since the initiation of LAN. Scores for the QLQ-C30 global health status were high (mean [SD] 65.5 [22.1], median [range] 66.7 [0–100]), while scores for the QLQ-GI.NET21 endocrine and gastrointestinal subscales were low (endocrine, mean [SD] 19.4 [21.3], median [range] 11.1 [0–100]; gastrointestinal, mean [SD] 22.9 [17.8], median [range] 20.0 [0–87]). Patients who expressed a high PSD score well on their overall rating of QoL (Table); in total, 70% of patients who were ‘rather’ or ‘completely’ satisfied had ‘good’, ‘very good’, or ‘excellent’ QoL.

Conclusion: In a real-world setting, CS symptom control with LAN treatment translates into favorable levels of satisfaction among patients with NETs. Higher satisfaction levels were consistent with higher global health QoL scores.
### Table. QoL according to PSD

<table>
<thead>
<tr>
<th>Overall QoL</th>
<th>‘Rather’ or ‘completely’ satisfied (n=200)</th>
<th>Neither satisfied nor dissatisfied (n=46)</th>
<th>‘Rather’ or ‘completely’ dissatisfied (n=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very poor, poor, or slightly poor</td>
<td>28 (14)</td>
<td>12 (26)</td>
<td>5 (28)</td>
</tr>
<tr>
<td>Neither poor nor good</td>
<td>32 (16)</td>
<td>12 (26)</td>
<td>6 (33)</td>
</tr>
<tr>
<td>Good, very good, or excellent</td>
<td>140 (70)</td>
<td>22 (48)</td>
<td>7 (39)</td>
</tr>
</tbody>
</table>